Insights On Enterprise Solutions

  1. ADCs vs. AOCs: Shared Design Principles & Key Differences In Bioconjugate Engineering 9/8/2026

    Discover how payload size, charge density, and linker dynamics shape clearance, loading ratios, and intracellular delivery in next-generation oligonucleotide bioconjugates.

  2. How To Choose A Biologics CDMO: The 4 Selection Criteria 9/8/2026

    Choose a biologics development and manufacturing partner with proven expertise, clear communication, flexible scale-up capacity, and a collaborative culture that reduces commercialization risk.

  3. Why The Traditional Approach To Evaluating Gene Editing Is Not Your Only Option 9/7/2026

    De-risk genetic medicine development with a phased evaluation approach. Gain rapid, data-driven feasibility insights before major investments, enabling smarter decisions and faster clinical progress.

  4. From Nature-Limited To AI-Designed: The Future Of Gene Editing 9/7/2026

    Generative AI is creating novel gene-editing proteins with greater precision and potency, expanding therapeutic possibilities while overcoming the limits of naturally evolved enzymes.

  5. What Makes A Base Editor Potent For Therapeutic SNP Correction? 9/7/2026

    Therapeutic SNP correction requires tailored enzymes and guide RNAs to boost on-target editing, reduce bystander effects, and enable precise conversion.

  6. The Next Base Editors Will Be Engineered, Not Found 9/7/2026

    Transitioning from wild-type enzymes to AI-engineered base editors overcomes biological limits. Custom deaminases enable precise single-nucleotide corrections with minimal bystander edits.

  7. Rapid Release Testing Starts With Faster Contaminant Detection 9/7/2026

    Switch to rapid sequencing-based contaminant detection to accelerate advanced therapy release timelines, minimize batch rejection risks, and bypass slow, culture-based testing methods.

  8. Can LNPs Replace Electroporation For T-Cell Engineering? 9/7/2026

    Replacing electroporation with lipid nanoparticles enables efficient non-viral T cell delivery, preserving cell health while supporting scalable manufacturing and high delivery performance.

  9. How Can AI-Directed Protein Engineering Improve Genomic Medicines? 9/7/2026

    Combining AI-driven modeling with automated cell profiling speeds protein optimization, identifying high-performing enzyme variants with greater potency and precision for genomic medicine applications.

  10. Targeted Gene Insertion Needs More Than One Tool 9/7/2026

    Targeted large gene insertion depends on matching the right mechanism to the biology. Engineered enzymes, recombinases, and retrotransposons help optimize efficiency and precision.